Current location - Music Encyclopedia - Earning online - Why can't China pharmaceutical stocks be bought?
Why can't China pharmaceutical stocks be bought?
Why can't China pharmaceutical stocks be bought?

China Pharmaceutical Co., Ltd., covering the whole industrial chain of pharmaceutical R&D production and sales, has strong industrial strength and core competitive advantage. Thanks to the support of national policies and the growth of market demand, the company's business scale continues to expand and its performance continues to grow steadily. Why can't the following small series buy China pharmaceutical stocks? Let's take a look, hoping to bring some reference.

Why can't China pharmaceutical stocks be bought?

Because internet channels can't be bought. According to the information about China pharmaceutical stocks, we know that China pharmaceutical stocks can't be bought, because they can't be bought through Internet channels. China Pharmaceutical Co., Ltd. said on February 26th, 2022, 65438+ that Paciclovir, an oral drug of Pfizer COVID-19, is a prescription drug, which needs to be purchased according to the diagnosis of the hospital and cannot be purchased through Internet channels.

China Pharmaceutical Group Co., Ltd. is the only central pharmaceutical enterprise directly managed by the State Council SASAC. Founded in 1998, it is a comprehensive life and health industry group with comprehensive strength and leading scale in China and even Asia.

The enterprise has a large healthy industrial chain integrating scientific and technological research and development, industrial manufacturing, logistics and distribution, retail chain, medical and health care, international operation and financial investment.

On August 2nd, 20021year, the Fortune Global 500 list was released, and China Pharmaceutical Group Co., Ltd. ranked 109.

China Pharmaceutical Group is making every effort to promote the comprehensive construction of its five platforms-modern logistics distribution integrated operation platform, Industry-University-Research integrated scientific and technological innovation platform, international operation integrated platform, medical and health industry platform and efficient management integrated integrated platform. Form five complete coverage networks-national pharmaceutical logistics distribution network, national drug retail chain network, national narcotic drug distribution network, national biological product marketing and cold chain distribution network, and national medical device consumables product distribution network. Promote the all-round development of the Group's eleven major businesses-modern pharmaceutical logistics and distribution, pharmaceutical retail, biological products, chemical pharmaceuticals, modern Chinese medicine, diagnostic reagents and chemical reagents, scientific instruments and medical devices, pharmaceutical scientific research and engineering design, pharmaceutical international operation and overseas industries, pharmaceutical exhibitions and media, and medical and health industries, and form an innovative enterprise with the core competitiveness of medical and health industries.

Can pharmaceutical stocks still be bought now?

You can buy it. In the long run, the trend of making money in the pharmaceutical industry still exists.

According to relevant data, at present, the per capita medical expenditure in China is only $420, while that in the United States is as high as $9,403 and that in Japan is $3,703. China's population structure and development trend are very similar to those of Japan. In contrast, there is room for per capita medical expenditure to increase nine times. In the long run, with the arrival of the aging population, the pharmaceutical industry will be a gold mine that investors can't ignore. In the short and medium term, coupled with the outbreak of COVID-19 in 2020, it has accelerated the outbreak of profit, performance and capital concern in the pharmaceutical industry. By the end of 20021and 65438+2, the total market value of A shares is about 80 trillion, and the pharmaceutical industry accounts for about 9%. Ten years ago, this figure was only 3%. With the escalation of medical consumption and the aging of the population, COVID-19 is surviving? The pharmaceutical industry is promising. There are two reasons:

1. With the aging of the population, the demand for medical care has exploded. You can certainly feel that the trend of population aging in China is becoming more and more obvious. We can use some data to illustrate this trend: by the end of 20 17, there were1580,000 people over the age of 65 in China, accounting for 1 1.39% of the total population, and the growth rate of the population over the age of 65 remained at around 10%. However, the probability of human illness will gradually increase with age. According to the forecast of China Health Statistics Yearbook, the number of chronic diseases among the elderly population in China is increasing.

Second, the defensive nature of the pharmaceutical industry is deeply loved by institutions. The pharmaceutical industry is a typical weak cyclical industry with high demand rigidity and low elasticity, which is less affected by the macro-economy. Therefore, the pharmaceutical industry has strong defensive characteristics. Even if the macro-economy of the whole country is depressed, the pharmaceutical industry index is likely to rise well. Take the Japanese stock market as an example. From 1992 to 20 12, Japan's economy fell into a "lost twenty years". The Nikkei index fell by 25.6%, the pharmaceutical industry index rose by 92%, and 14 pharmaceutical industry index all outperformed the Nikkei index. On the other hand, A shares have the tradition of "drinking and taking medicine". When the market is bad, institutional funds will hold liquor stocks and pharmaceutical stocks together. Without him, liquor and medicine have performance support. Alcohol and medicine have always been the core of this organization. Now smog, gutter oil and other problems, it's hard to say what diseases China people will get in the future, but one thing is certain, there will be a great demand for drugs in the future. Strong industry demand and strong market recognition. This is the core reason of the myth of making money in the pharmaceutical industry. Generally speaking, the pharmaceutical industry is a track worthy of our long-term attention.

What pharmaceutical stocks are there in China?

1, Hengrui Pharma

Jiangsu hengrui Pharmaceutical Co., Ltd. was established on April, 2007 1997 with the approval of Jiangsu Provincial People's Government and initiated by five sponsors including Lianyungang Hengrui Group Co., Ltd. It is the largest research, development and production base of anti-tumor drugs in China.

2. East China Medicine

Hangzhou Huadong Pharmaceutical Group Company, formerly known as Zhejiang Pharmaceutical Factory, was founded in 1952, and later renamed Hangzhou No.2 Pharmaceutical Factory and Hangzhou Huadong Pharmaceutical Factory.

199265438+February 16, Hangzhou Huadong Pharmaceutical Group Company was established on the basis of Hangzhou Huadong Pharmaceutical Factory, and has now developed into a joint-stock enterprise-Huadong Pharmaceutical Co., Ltd., four Sino-foreign joint ventures (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Hangzhou Moshadong Pharmaceutical Co., Ltd., Hangzhou Jiuyuan Genetic Engineering Co., Ltd., Zhejiang Huayi Pharmaceutical Co., Ltd.).

3. Huahai Pharmaceutical

Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989, formerly known as Linhai Hongqiao Synthetic Chemical Plant. 200 1 changed to Zhejiang huahai pharmaceutical co., ltd as a whole. In March 2003, the company's shares were successfully listed on the Shanghai Stock Exchange. Stock abbreviation: Huahai Pharmaceutical, stock code: 60052 1.

4. Puli Pharmaceutical

Established in 1992, Hainan Puli Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production and sales of chemical pharmaceutical preparations, and has passed the certification of leading pharmaceutical enterprises in China. The company has two wholly-owned subsidiaries, Zhejiang Puli Pharmaceutical Co., Ltd. and Hangzhou Saili Pharmaceutical Research Institute.

5. Jingxin Pharmaceutical

Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974, and has now developed into a national key high-tech enterprise and one of the top 100 pharmaceutical enterprises in China. In July 2004, it was successfully listed on Shenzhen Stock Exchange.

6. Xinlitai

Shenzhen Xinlitai Pharmaceutical Co., Ltd. was approved by the Ministry of Commerce of People's Republic of China (PRC) "Reply on Agreeing to the Restructuring of Shenzhen Xinlitai Pharmaceutical Co., Ltd. into a Chinese-foreign Joint-stock Enterprise" (CSRC Permit [2007] 10 16) and obtained the "Approval Certificate of China People's Taiwan, Hong Kong, Macao and Overseas Chinese Investment Enterprise" issued by the Ministry of Commerce. On June 29th, 2007, Shenzhen Xinlitai Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Xinlitai") was established as a wholly foreign-owned company with a registered capital of 85 million yuan, and obtained the Business License of Enterprise as a Legal Person with the registration number of 44030150124347.

What is the stock code of China Medicine?

The stock code of China Pharmaceutical is 600056. If you want to know more information, you can download a stock software to check it out. I hope the answer will help you.

Can China pharmaceutical stocks be held for a long time?

Of course. Although compared with foreign countries, China's pharmaceutical stocks have a heavy bubble, with the support of continuous policies, they are still good varieties to fight inflation and economic cycle.

China Pharmaceutical Group Co., Ltd. is the only central pharmaceutical enterprise directly managed by the State Council SASAC. Founded in 1998, it is a comprehensive life and health industry group with comprehensive strength and leading scale in China and even Asia.

The enterprise has a large healthy industrial chain integrating scientific and technological research and development, industrial manufacturing, logistics and distribution, retail chain, medical and health care, international operation and financial investment.

On August 2nd, 20021year, the Fortune Global 500 list was released, and China Pharmaceutical Group Co., Ltd. ranked 109.

China Pharmaceutical Group is making every effort to promote the comprehensive construction of its five platforms-modern logistics distribution integrated operation platform, Industry-University-Research integrated scientific and technological innovation platform, international operation integrated platform, medical and health industry platform and efficient management integrated integrated platform. Form five complete coverage networks-national pharmaceutical logistics distribution network, national drug retail chain network, national narcotic drug distribution network, national biological product marketing and cold chain distribution network, and national medical device consumables product distribution network. Promote the all-round development of the Group's eleven major businesses-modern pharmaceutical logistics and distribution, pharmaceutical retail, biological products, chemical pharmaceuticals, modern Chinese medicine, diagnostic reagents and chemical reagents, scientific instruments and medical devices, pharmaceutical scientific research and engineering design, pharmaceutical international operation and overseas industries, pharmaceutical exhibitions and media, and medical and health industries, and form an innovative enterprise with the core competitiveness of medical and health industries.

Pharmaceutical Group has a distribution network covering 365,438+0 provinces, autonomous regions and municipalities directly under the Central Government and 30 distribution centers that meet international standards. It is the largest biomedical R&D and production enterprise in China, and has undertaken more than 80% of the production tasks of the national immunization program vaccines. The group has established production bases and medicinal materials bases for biopharmaceuticals, narcotic psychotropic drugs, anti-infective drugs, anti-tumor drugs, cardiovascular and cerebrovascular drugs and respiratory drugs, and has the strongest applied drug research institutions and engineering design institutes in China.